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Background: We tested the hypothesis that a novel vaccine developed from autologous dendritic cells (DC)
loaded with cells from a unique allogeneic brain tumor cell line (GBM6-AD) would be well-tolerated and would
generate an immune response.
Method: Patients with recurrent primary brain tumors underwent vaccination with GBM6-AD/DC vaccine. Subjects
were treated at escalating DC cell doses: 5 × 106 (one patient), 10 × 106 (one patient) and 15 × 106 (6 patients).
Subcutaneous injections were planned for days 0, 14, 28, 42, 56, and monthly thereafter. The primary endpoint was
the safety of the GBM6-AD/DC vaccination. The secondary endpoints were immune response, measured by flow
cytometry, and the clinical outcome of tumor response defined by time to progression and overall survival.
Results: Eight patients were treated. The first three patients were treated in the dose escalation phase of the trial;
the remaining five patients received the maximum dose of 15 × 106 DC. No dose limiting toxicity was observed.
The best response per modified McDonald criteria was partial response in one patient. Flow cytometric immune
profiling revealed significant differences in CD4+IL17+ lymphocytes and myeloid derived suppressor cell populations
between patients characterized as having stable vs. non-stable disease.
Conclusion: This first-in-human study shows that the GBM6-AD/DC vaccine was well tolerated and was associated
with an immune response in a subset of patients. No MTD was achieved in this trial. This small-scale pilot provides
information for larger scale investigations into the use of this allogeneic vaccine source.
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Primary brain tumors continue to represent a significant
therapeutic challenge. Current standard therapy employing
radiation and temozolomide for WHO grade IV astrocy-
toma (glioblastoma multiforme) has resulted in extending
the median survival from 12.1 months to 15 months
[1,2], with greater than 85% of the patients dying within* Correspondence: olin0012@umn.edu
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unless otherwise stated.3 years [3,4]. Likewise, recurrent pediatric tumors such
as infratentorial ependymoma and medulloblastoma con-
tinue to have poor prognoses.
Given the lack of progress with current therapy, increased
attention has been placed on therapeutic vaccination as a
route to improved disease outcome and quality of life for
these patients. Autologous tumor cells are frequently used
as the source of vaccine antigen, functioning as personal-
ized immunotherapy by targeting multiple patient-specific
tumor antigens [5,6]. Vaccines utilizing tumor cells include
tumor lysate-pulsed DCs [7-9], tumor-derived heat shock
proteins [10], and whole tumor cell lysates [11-14]. A. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vaccine for both high- and low-grade glioma (Clinicaltrials.
gov). However, the use of patients’ resected tumors has a
number of drawbacks and limitations. Autologous tumor-
based vaccines require the removal and processing of the
tumor to derive lysate. Although this process may result in
an abundant amount of material, the yield of tumor cells
may be low. In addition, contamination with impurities
such as non-tumor derived endothelial cells, fibroblasts,
leukocytes or other stromal cell types may occur. In some
trials, resected tumors are cultured to purify tumor cells.
However, the ability to expand the culture varies from
tumor to tumor, potentially resulting in a lack of material
for continued treatment. Moreover, if tumor resection is
not an option, the patient is ineligible for treatment.
In this study, we used autologous dendritic cells (DCs)
loaded with apoptotic bodies derived from an allogeneic
glioma cell line (GBM6-AD) with a high expression of
multiple tumor and tumor-associated antigens. To enhance
immunogenicity, we incubated the cell line in physiologic
(5%) oxygen, which we have previously reported to produce
superior immunogenicity compared to cell lines grown
under atmospheric (20%) oxygen conditions [11,15]. The
purpose of this clinical trial was to evaluate the feasibility
and toxicity of a novel DC vaccine loaded with antigen
derived from our tumor cell line [15]. Our data suggest that
this vaccine approach, using an allogeneic antigen source, is
safe and induces potentially therapeutic immune responses
in a subset of patients. In addition, by measuring various
immune parameters, we discovered an increase in produc-
tion of cytokine IL17a in patients demonstrating response
to therapy.Results and Discussion
Patient characteristics
Twelve patients were enrolled for this single institution
study. All underwent apheresis. 2 patients withdrew due
to rapid disease progression, 1 patient withdrew volun-
tarily, and 1 patient was declared ineligible due to the
diagnosis of supratentorial PNET upon pathology re-
view. Of the 8 patients who received vaccine treatment,
one patient was not evaluable after having received only
a single vaccine due to post-operative complications. All
of the patients had received at least one prior treatment
regimen containing temozolomide. 2 patients received
prior bevacizumab; one of these patients also received cis-
retinoic acid. We also made an effort to create a minimal
residual disease state when possible, performing debulking
surgeries in three subjects (patients 2, 3 and 8) prior to ini-
tiating vaccine therapy. All subjects were off dexametha-
sone therapy at the time of study enrollment.
At study entry, the mean absolute white blood cell
count was 5,037 × 109/L (range: 3,600 - 13,000 × 109/L)and the mean absolute lymphocyte count was 1,162 ×
109/L (range 500 – 2,100 × 109/L).
Dose escalation and toxicity
No MTD was reached. The only non-DLT toxicities
observed were fatigue (patient 7) and skin reaction at the
vaccine injection site. The maximum area of localized ery-
thema and induration observed at the injection site was
3 × 7 cm (patient 7). Patient 1 had deep venous throm-
bosis prior to vaccine administration that continued
throughout his treatment course. No systemic reactions
or anaphylaxis episodes were noted throughout the trial.
Response evaluation
The median number of vaccines administered was 4.5
(range, 1–12). Patient 4 had received bevacizumab prior
to study entry. She met criteria for progression at week
13, but survived to 64.8 weeks after first vaccine. Patient
5 demonstrated multifocal tumor involvement at study
entry, had a partial response by week 8 (Figure 1), and
then failed distantly from his primary tumor sites at
32 weeks from first vaccine. Patients 5, 6 and 7 had
stable disease for 30.6, 39.7 and 20 weeks respectively
(Table 1). Patient 6 did not meet dimensional measure-
ment criteria for progression, but had changes on perfu-
sion imaging that led to biopsy and documentation of
progressive disease. Hence, his therapy was terminated.
Patient 7, with posterior fossa ependymoma, experienced
recurrence at two distant intradural extramedullary spinal
metastatic sites at thoracic spine levels 6 to 8 and lumbar
vertebral levels 4 to 5. The remaining 7 of 8 evaluable pa-
tients experienced progression at their primary tumor site.
Two patients (patient 6 and 7) remain alive off protocol
therapy; patient 6 received metronomic temozolomide
and is currently receiving bevacizumab 92 weeks from first
vaccine and patient 8 received sunitinib and is 72 weeks
from first vaccine. Patient groups were defined in a post
hoc analysis as stable if they exhibited no progression at
week 8 of vaccine therapy and non-stable if they showed
progression at or before week 8.
Patient evaluation
To determine if the immune response correlates with
clinical observations, we divided patients into stable and
non-stable populations based on time on trial and im-
mune response (see Table 1).
Phenotypic biomarkers
Myeloid-derived suppressor cells (MDSCs) represent a
heterogeneous population of myeloid progenitor cells and
immature myeloid cells. MDSCs suppress T cell function
through the production of arginase-1, nitric oxide and re-
active oxygen species [16]. Elevated numbers of MDSCs in
peripheral blood have been demonstrated in a substantial
Figure 1 Partial response in-patient following vaccination. Axial and coronal MR images of a 17-year-old male with recurrent glioblastoma multi-
forme (patient 5) showing a partial radiographic response. Images show his scans at initiation of therapy (A, B), at week 8 (C, D) and week 20 (E, F).
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malignant glioma [17], head and neck cancer [18,19], inva-
sive breast carcinoma [19], colon carcinoma [19] and
mesothelioma [20]. The data presented in this manuscript
demonstrate the same trend; we focused on the clinically
stable and non-stable populations. In this study, patients 4,
5, 6 and 7, who were characterized with stable disease,
had a statistically significant decrease in Lineageneg
(CD3-CD14-CD16-CD19-CD56-) HLA-DR-CD33+ MDSCsTable 1 Vaccine release criteria was determined by pathogen
Assay Test method





Sterility (14 days) Bactec
Mycoplasma PTC (28 day culture)(Figure 2A) and monocytic MDSCs (CD14+HLA-DRlo)
(Figure 2B). We did observe a statistically significant
increase in the percentage of granulocytic MDSC
(CD15+CD14-) (Figure 2C) in patients with non-stable
vs. stable disease. The increased absolute number of
granulocytic MDSCs in the non-stable group failed to
reach statistical significance. No difference in Tregs
was observed between patient populations (data not
shown).load and phenotypic markers




<0.7 (<0.4-1.030) <5 EU/mL
No organisms No organisms
No growth No growth
Negative Negative
Figure 2 Non-stable patients have higher MDSC populations. Patients’ whole blood was stained with antibodies to analyze A. MDSC
(Lineage negative), B. monocytic MDSC, and C. granulocytic MDSC populations from patients prior to vaccination. Error bars, ± SEM. *P < 0.05.
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tool to follow response to immunotherapy, we followed
the development of effector and central memory CD4+
and CD8+ T cell populations throughout each patient’s
time on the trial. CD4+ and CD8+ central memory popu-
lations sharply decreased and CD4+ and CD8+ effector
memory populations increased by week 24 in our stable
patient group (Additional file 1: Figures S1A-H). These
observations failed to meet statistical significance between
stable and non-stable groups. However, there was a signifi-
cant increase of CD8+ central memory T cells (p = 0.037)
in the stable disease population from week 0 to 24.
To test our predictions regarding the stable and non-
stable patient populations, phenotypic markers from the
patients were blindly normalized from healthy donors
and imported into Partek Genomics software for hier-
archical analysis as described by Gustafson et al. [21].
This categorized the same patients into the same groups
that we predicted to be stable or non-stable populations(Figure 3) with the exception of patient 8, who was
placed in the non-stable group based on her time on
trial as a criterion. Using cluster analysis, the program
placed her more closely immunologically to the stable
patient population than the non-stable population. Inter-
estingly, although she went off trial early due to progres-
sive disease, patient 8 remains alive with disease.
Cytokine production
To further investigate an immune response to vaccination,
patients’ immature dendritic cells were pulsed with the vac-
cine derived tumor lysate, maturated and then incubated
with peripheral blood mononuclear cells (PBMCs) from
each patient at different time points. Supernatants were har-
vested and assayed for cytokine elaboration. Following lysate
stimulation, patient cells produced GM-CSF (Figure 4A),
TNFα (Figure 4B), IL-17a (Figure 4C), and IFNγ (Figure 4D).
PBMCs from patients were incubated with non-lysate
pulsed DCs as a control and no cytokine response was
Figure 3 Hierarchical clustering of immune phenotypes validates predicted stable and non-stable patient populations. Phenotypic
values were normalized to healthy donors and imported into genomic software for hierarchical clustering.
Figure 4 Patients’ cytokine profiles are altered following vaccination. Patients’ PBMCs were stimulated with tumor lysate-pulsed dendritic
cells, maturated and analyzed for A. GM-CSF, B. TNFα, C. IL-17a, and D. IFNγ production. E-H. To determine the difference between stable and
non-stable patient populations, concentrations of GM-CSF, TNFα, IL-17a, and IFNγ cytokine production was analyzed between the two groups.
Each patient was run in triplicate, error bars ± SEM, *P < 0.05.
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elaboration of GM-CSF (Figure 4E) and TNFα (Figure 4F)
between days 0 and 12 in the stable patient group. In
addition, an increase of IL-17a was observed, (Figure 4G).
However, it failed to reach statistical significance. No IFNγ
difference was observed between groups (Figure 4H). Inter-
estingly, there was no detectable IFNγ production by patient
8 throughout the trial (Figure 4D).
CD4+ T cells were primarily known to be Th1, Th2, or
Treg cells; however, more recently, a subset of IL-17a–
secreting CD4+ T cells (Th17 cells) has been characterized
[21,22]. Further studies have reported that MDSCs are able
to modulate the induction of Th17 cells from CD4+ T cells,
and also catalyze the differentiation of Foxp3+ regulatory
T cells from monocyte-induced Th17 cells [23]. In this
study, we observed an increase of IL-17a in the stable
patients. Therefore, we repeated our experiment by harves-
ting cells 24 hours post stimulation and analyzed total intra-
cellular IL-17a production. We observed the same trend as
seen in total secreted IL-17a production (Figure 5A).Figure 5 CD4 T cell produce IL17. Patients’ PBMCs collected on or days 4
immature dendritic cells and analyzed for A. total IL-17a production and B t
C. CD4 T cells were analyzed for intracellular IL-17a production. Each patientPlotting percentages of total IL-17a producing cells against
concentrations of secreted protein demonstrated the same
trend of total IL-17a in patients over time (Figure 5B). To
determine which T cell population is responsible for the
production of IL-17a, we repeated the experiment. Using
flow cytometry, by gating on the CD3+ population, we deter-
mined that IL-17a is produced by CD4+ T cells (Figure 5C).
Due to the lack of effective treatment for malignant
brain tumors, extensive effort has been applied to the de-
velopment of new immunotherapeutic approaches. This
study represents the first-ever use of an allogeneic cell
source for vaccine immunotherapy of individuals with
these diseases. Numerous practical difficulties are encoun-
tered in personalized therapy using autologous material.
Therefore, we sought to derive a novel highly immuno-
genic allogeneic cell line expressing high levels of multiple
tumor antigens for use in a DC vaccine. In this phase I
study, twelve patients were enrolled; two patients were
unable to proceed with vaccine due to rapid disease
progression following apheresis, one patient was ineligiblethrough 24 post vaccination were stimulated with tumor lysate-pulsed
otal secreted IL-17a plotted with percentages of IL-17a producing cells.
was run in triplicate, error bars ± SEM, *P < 0.05.
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luable following treatment for a pre-existing surgical
complication after only one vaccine dose. Eight patients
ultimately received the vaccine generated by incubation of
DCs with allogeneic glioma cell line GBM6-AD at dose
levels of 5 million, 10 million and 15 million DCs. No
DLTs were encountered. We are encouraged by the obser-
vations of partial response in one patient and prolonged
survival achieved after protocol therapy in 2 other patients.
The problem of vaccine feasibility in the face of tumor pro-
gression, especially after discontinuation of bevacizumab
therapy, is significant given the very malignant nature of
the tumors in our treatment subjects. This was especially
evident in the patients who underwent apheresis, but
progressed prior to initiation of vaccine therapy and patient
4, who had post-bevacizumab radiographic changes (data
not shown) and eventual progression by our study criteria.
We sought to use immune biomarkers and cytokine
profiling throughout the study to discern a correlation with
clinical response. Using these markers, we separated our
patients into stable and non-stable patient populations.
This separation not only revealed a significant increase in
MDSCs in the non-stable patient population (Figures 1A-C),
but also revealed a significant increase in the absolute
number of natural killer cells in both healthy donor and
stable populations compared to non-stable patients (P = 0.02
and P = 0.04 respectfully) (Additional file 2: Figure S2). The
reduced natural killer population in non-stable patients
may result in reduced IFNγ production and decreased
tumoricidal response. In addition, although not statistically
significant, we observed an increased CD8+CTLA-4+
population in non-stable patients (data not shown), infer-
ring that the checkpoint blockade inhibitor ipilimumab
may be beneficial in this population.
CD4 T cells have recently been characterized to pro-
duce IL-17a [24], and it has been reported that the ma-
jority of IL-17a - producing effector cells produce IL-2
and TNFα, but fail to produce IFNγ or granzyme B
[24,25]. In the present study, we saw a similar trend in
one of our patients, patient 6, who was characterized as
stable and failed to produce IFNγ. This patient did dem-
onstrate a significant increase in IL-17a by week 8 that
continued throughout his participation in the trial. The
lack of IFNγ production may be due to the lack of CD4+
T cells. Throughout the study, this patient had an
average 26% CD3+ CD4+ population, the lowest of any
patient. Interestingly, from this low percentage of CD3+
CD4+ population, patient 6 maintained an average of
9.1% naïve CD4+ (CD4+CD27+CD45RA+CD62L+) T cell
population, the lowest of all patients, but had an average
of 52.4% memory (CD4+CD27+CD45RA+CD62L) CD4 T
cells, the highest of all patients. Although this patient
went off trial, he had the longest progression free survival
(39.7 weeks) and survived for >100 weeks post vaccination.Conclusions
This study was designed to determine the safety of a novel
allogeneic brain tumor vaccine. While we accomplished
this goal, we also performed post-hoc analyses to deter-
mine the usefulness of phenotypic biomarkers and cytokine
production to follow the efficacy of the vaccine in produ-
cing an immune response. We discovered a potential cor-
relation of MDSC levels with response to vaccination. This
is important because understanding the mechanism (s)
allowing the disease to escape treatment will allow us to
modify our therapy to better suit future patients. By meas-
uring in-vivo phenotypic markers and cytokine responses
ex-vivo, we were able to follow alloresponses to vaccine
over time in the stable patient population. Such marker
analyses will be important in evaluating the effectiveness
of future vaccine trials and may be prognostically import-
ant for patients being considered for immunotherapy.
While this study demonstrates safety in the use of a novel
allogeneic vaccine, we show the potential importance of
using specific biomarkers to evaluate and predict vaccine
effectiveness. We do acknowledge that this study is under-
powered. Therefore, based on our observations, our future
study design will focus on the biomarkers reported in this
manuscript. Despite the small patient number in this pilot
study, we believe this is important information to carry
forward to future brain tumor immunotherapy trials.
Methods
Patients and eligibility
The protocol outline can be obtained at http://clinical-
trials.gov/ct2/show/NCT01171469?term=dendritic+cell++
brain&rank=1. The University of Minnesota institutional
review board approved the study. Informed consent was
obtained from patients 18 years of age and older and from
the parents/legal guardians of patients less than 18 years.
Patients with histopathologically confirmed glioblastoma
multiforme (WHO Grade IV), ependymoma and medullo-
blastoma were eligible for this trial. Pediatric subjects were
ages 0 through 17 years and adult subjects were 18 years
and above. All patients were required to have received and
failed standard-of-care therapy for their respective tumor
and had a performance score of at least 60 based on the
Lansky play performance scale for patients 0 – 15 years
and a Karnofsky performance status of at least 60% for
patients 16 years and older. Patients were required to
have adequate baseline bone marrow, hepatic and renal
function. All female patients of child bearing potential
had a negative pregnancy test. Patients were excluded
for uncontrolled intercurrent illness including, but
not limited to, ongoing or active infection, symptomatic
congestive heart failure, unstable angina pectoris, or psy-
chiatric illness/social situations that would limit compli-
ance with study requirements or if they were currently
receiving any other investigational agents. Patients who had
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munity (e.g., autoimmune diseases) and hypoimmunity
(e.g., myelodysplatic disorders, marrow failures, AIDS,
ongoing pregnancy, transplant immuno-suppression) were
also ineligible, as were patients with conditions that could
potentially alter immune function (diabetes, renal failure,
liver disease, severe nutritional depletion).Dendritic cell generation
At enrollment, each patient underwent leukapheresis
to obtain peripheral blood mononuclear cells. The
patient subjects were required to complete a donor
questionnaire/screen comparable to current standard
blood center collection practice, and standard tests for
infectious diseases were performed. Infectious disease
testing included screens for HIV and HCV (by nucleic
acid testing), anti-HIV I/II, anti-HTLV I/II, anti-HBc
Ab, HBsAg, anti-HCV, anti-CMV and Treponema
pallidum (by serology). One standard-volume (e.g.,
12–15 L) of non-mobilized apheresis product was
enriched for monocytes using the Miltenyi Biotec Clin-
iMACS® Cell Selection System and CD14 MicroBeads
and reagent (Miltenyi Biotec, Bergisch Gladbach,
Germany). This system typically yields ≥ 60% recovery
and ≥ 90% purity. Approximately 8 × 108 monocytes
went into the culture system (polystyrene tissue
culture flasks; 37°C at 5% CO2) at a concentration of
3–5 × 106 cells/mL, GM-CSF (25 ng/mL) and IL-4
(40 ng/mL) were added in addition to fresh medium
measuring one third of the volume of the initial cul-
ture, were added on day 3 and day 5 to derive imma-
ture dendritic cells (iDC). Cells were then maturated
by adding GM-CSF (50 ng/ml), IL-1β25 ng/mL), TNF-
α (50IY/μλ), Poly-IC (20 ng/ml), IFN-α (1500IY/μλ),
IFN-γ (3,000 units /mL) and incubated at 37°C for
2 days. Mature DCs were harvested on day 7 and were
cryopreserved and stored until they were incubated
with tumor cell lysate at a later date. A DC yield of
25-30% was expected (approximately 2 × 108 DCs).
Analysis by flow cytometry (CD1a, CD14, CD16,
CD83, CD86, HLA-DR) was used to characterize the
final product. Mature DC purity was expected to be
≥70%. An initial viability assessment was performed on a
pre-processing aliquot and on a sample drawn from the
final product. Viability testing was performed by flow
cytometry [e.g., 7-amino actinomycin D (AAD)]. A viability
of ≥70% was expected on the final product.Vaccine development
We established an allogeneic brain tumor stem cell line
(GBM6-AD) that was used as the source of tumor antigen
based on the cell line’s high expression of tumor stem cell
markers, tumor associated antigens, immunogenicity andrapid growth in culture [15]. The original brain tumor spe-
cimen was delivered on ice in a tube containing Neuroba-
sal (NB) media (Invitrogen). Upon arrival to the laboratory,
tumor tissue was transferred to NB supplemented with
50 ng/mL bFGF, 50 ng/mL EGF, 5 μg/mL gentamicin, and
0.9 μg/mL Fungizone under serum free conditions. The
tissue was transferred to a Petri dish and minced using
scalpels until the tissue particles were of a size that could
be drawn in and out of a 10 ml pipet. The cell suspension
was strained to remove any connective tissue. The cells
were washed in PBS and once in Red Blood Cell Lysis solu-
tion. Cultures were grown in a cell culture incubator at 37°
C, 5% O2, and 90% relative humidity in culture medium
consisting of: DMEM/F12 w/ L-glutamine and sodium bi-
carbonate (Invitrogen), B27 supplement (0.5×) (Invitrogen),
N2 supplement (0.5×) (Invitrogen), 20 ng/ml human EGF
(Pepprotech), 20 ng/ml human FGF (Pepprotech), 1× non
essential amino acids (Gibco), 1% penn/strep (Gibco), and
10 mM Hepes (Gibco) until confluent. To generate apop-
totic bodies, adherent GBM6-AD cells were incubated be-
tween 44- 46°C in an incubator for 3 hours and returned
to 37°C. After 24 hours, cells were harvested, washed, and
irradiated (200 Gy) and cryopreserved in 10% DMSO.
Apoptotic bodies were added to cultured iDCs and matu-
rated as described above. Vaccine was stored at −150°C in
liquid nitrogen vapor. All final product was required to
pass lot release criteria prior to use (Table 2).
Each patient received a single subcutaneous injection
of vaccine (see Table 1) given in alternating suprascapu-
lar areas after topical imiquimod pre-administration at
the vaccine injection site. Imiquimod was then adminis-
tered again to the injection site at 24 hours post-vaccine.
Imiquimod is marketed as 5% Aldara cream in 250 mg
packets, providing a total dose of 12.5 mg per packet,
which is sufficient to cover 20 square centimeters. The
contents of one half packet were applied as a thin film
to cover approximately 10 square centimeters of skin in
the area of the vaccination. The imiquimod was rubbed
in well using a gloved finger. The leftover imiquimod was
disposed of and a new packet used for each application.
Patients were observed for 30 minutes after each injection
for immediate systemic or injection site adverse events.
Study design
The study protocol dictated vaccine administration at
day 0 and every two weeks for the first 8 weeks. There-
after, re-vaccination was administered every 4 weeks up
to an additional 10 vaccinations for patients without dose
limiting toxicity (DLT) or disease progression defined by
greater than 25% tumor growth on MRI. This study used
an accelerated dose escalation design (1 subject per level),
after which a traditional phase I design (3 subjects per
level) was implemented. DLT was defined as Grade 3 or
greater treatment related toxicity in association with the
Table 2 Median age of patients 48.5 (3–71)













Patient 1 71 Male 80 GBM 2 4.2 34.6 ISR/1 Non-stable
Patient 2 61 Male 90 GBM 4 8 12.4 Non-stable
Patient 3 42 Female 80 GBM I Not evaluable N/A Non-stable
Patient 4 55 Female 90 GBM 5 13.0 64.8 ISR/ 1 Stable
Patient 5 17 Male 70 GBM 10 30.6 53.3 lSR/1 Stable
Patient 6 63 Male 90 GBM 9 39.7 >92 ISR/1 Stable
Patient 7 3 Female 60 Epend 6 20.0 31.4 Fat/i
ISR/3 Stable
Patient 8 24 Female 90 Med 5 8.0 >92 Non-stable
Patient 9 53 Male 80 GBM 0 N/A N/A Non-stable
Patient 10 13 Female 90 PNET 0 N/A N/A Non-stable
Patient 11 49 Male 80 GBM 0 N/A N/A Non-stable
Patient 12 48 Male 80 GBM 0 N/A N/A Non-stable
Male: Female 4:4. prior treatment regimes median (range) 1.5 (1–4). Performance Status (KPSansky), GBM Glioblastoma (WHO Grade IV), Epend = Ependymoma.
Med = Medloblastoma, PNRT = primitive neuroectodemial tumor. ISR = Injection site skin reaction. Fat = Fatigue. Survival is measured in weeks post treatment
Patients 9–12 failed trial prior to vaccination.
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ation to the next dose level did not occur until the patient
(s) in the previous cohort were at least 4 weeks post the
initial vaccination. Patients 1 and 2 received 5 million and
10 million DCs, respectively. Patients 3 through 8 received
15 million DCs.
Toxicity assessment and disease evaluation
Toxicity monitoring included medical history, physical
examination, complete blood counts and serum chemis-
tries prior to each vaccine episode. DLT was defined as
Grade 3 or greater treatment related toxicity. Toxicity and
adverse events were classified according to NCI’s Common
Terminology Criteria for Adverse Events V 3.0 (CTCAE).
Skin reactions of Grade 3 were not defined as a DLT.
Subjects were evaluated using 3 Tesla MRI to determine
tumor size prior to treatment to obtain a baseline meas-
urement. Subjects were then re-evaluated by 3 Tesla MRI
at monthly intervals through the first 3 months of treat-
ment and once every 3 months thereafter.
Immune assessment
Blood was drawn from patients 2 weeks prior to vaccin-
ation, at vaccination, and on weeks 4, 8, 12, and 24. Puri-
fied peripheral blood mononuclear cells were analyzed for
cytokine analysis, whole blood was analyzed by flow cy-
tometry for MDSC ((Lineage-negative), FITC (CD3, CD14,
CD16, CD19, CD20, CD56) CD33-APC, HLA-DR-
PerCp)), monocytic MDSC (CD14-APC, HLA-DR-PerCp),
granulocytic MDSC (CD15-FITC, CD14-APC), CD8 cen-
tral and effector memory (CD45RO-PE, CD8-PerCp,
CD62L-APC, CCR7-FITC) and CD4 central and effectormemory (CD45RO-PE, CD4-PerCp, CD62L-APC, CCR7-
FITC) populations. 5 × 105 patient immature dendritic
cells were suspended in 1 ml of AIM V media (Life Tech-
nologies) and pulsed with 10 μg of tumor lysate derived
from the vaccine cell line and maturated with human
recombinant GM-CSF (50 ng/ml), IL-4 (40 ng/ml), IL-1β
(25 ng/mL), TNFα (50 ng/mL), Poly-IC (20 ng/mL), IFN-α
(1500IY/μλ), and IFNγ (3,000 units/mL). Cultured DCs
were washed twice and 1 × 106 PBMCs isolated from each
patient at weeks 0, 4, 8, 12, and 24 were added to DCs and
incubated for 48 h. Supernatants (50 μl) was removed and
analyzed for IFNγ, GM-CSF, TNFα, and IL-17a. To valid-
ate cytokine production, in separate wells, PBMCs were
incubated with maturated DCs for 24 hrs, Golgi Stop (BD
Biosciences) at a final dilution of 4 μl/6 ml was added to
wells. PBMCs were labeled with CD3-APC, CD4-FITC,
CD8-PE, fixed and permiabilized (BD Biosciences) and
stained with IL-17a eFluor450. Cells were washed and
analyzed by flow cytometry. In both sets of experiments,
non-tumor lysate pulsed DCs were used as a control.
Hierarchical clustering of immune phenotypes
Conversion of immune phenotypes to cells per micro-
liter and hierarchical clustering of immune phenotypes
were performed. In this study, the phenotypic values
were normalized by dividing the value by the mean value
of healthy volunteers. The immune phenotype ratios were
imported into Partek Genomics Suite 6.6 software (Partek
Inc., St. Louis, MO) and log-transformed for hierarchical
clustering. Hierarchical analysis was performed by un-
supervised agglomerative Euclidean average linkage clus-
tering [21].
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In this study, we established four response categories
based on a modification of the criteria proposed by
MacDonald et al. [26]. Complete responses (CR) are
those in which there is a disappearance of all enhancing
tumor or tumor mass on consecutive MRI scans. Patients
must be off steroids, and neurologically stable or im-
proved. Partial responses (PR) are those in which there is
a ≥ 50% reduction in the size of the enhancing tumor or
tumor mass on consecutive MRI scans. In addition, the
patient must be neurologically stable or improved. A pro-
gressive disease (PD) state is one in which there is ≥ 25%
increase in the size of the enhancing tumor or tumor mass
on MRI scans, or the patient is neurologically worse, and
steroids are stable or increased. A stable disease (SD) state
is all other situations. If patients initially exhibit tumor
regression or a stable response for a period of time
followed by progressive disease, this would be viewed as a
relapse.
Statistical comparisons were made by comparisons
using a 2-tailed t-test. All tests were performed with Prism
4 software (Graph Pad Software, Inc). P values <0.05 were
considered significant.Additional files
Additional file 1: Figure S1. Effector and memory T cell populations
responded to vaccination in the stable patient population. Patients’
whole blood was stained with antibodies to measure A. CD4 central
memory, B. CD8 central memory, C. CD4 effector memory and D. CD8
central memory populations. Patients are individually plotted in plots
A-D. E-H. Percentages from stable and non-stable patient populations
were combined to analyze various cell phenotypes. Each patient was run
in triplicate, error bars ± SEM, *P < 0.05.
Additional file 2: Figure S2. The stable patient population has a higher
natural killer population. Patients’ whole blood was stained with
antibodies to analyze natural killer populations from patients prior to
vaccination. Each patient was run in triplicate, error bars ± SEM, *P < 0.05.Competing interest
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